From Hyper to Hypo Fractionation in Radiation Oncology

September 8-11, 2013 • Wisconsin Institutes of Discovery • Madison, Wisconsin, USA

Endorsed by:
American Association of Physicists in Medicine

Organizers
9th International Conference on Dose, Time and Fractionation in Radiation Oncology
From Hyper to Hypo Fractionation in Radiation Oncology

Sponsored by:
University of Wisconsin School of Medicine and Public Health
University of Wisconsin Carbone Comprehensive Cancer Center
Department of Human Oncology
The Office of Continuing Professional Development in Medicine and Public Health

SEPTEMBER 8-11, 2013 • MADISON, WISCONSIN, USA
The University of Wisconsin School of Medicine and Public Health is organizing a 4-day conference, September 8 -11, 2013, on “From Hyper to Hypo Fractionation in Radiation Oncology.”

Optimization of dose-time-fractionation remains a central research theme in radiation oncology. Intriguingly, the focus has shifted over a relatively short period of time from the use of hyperfractionation (i.e., fraction sizes lower than the standard 2 Gy per fraction) to hypofractionation that is the use of fraction sizes larger than 2 Gy, as a strategy for improving patient outcome. This shift has occurred as a result of advances in both radiation biology and in physics and technology. Advances in radiation biology include an improved understanding of the fractionation biology of tumors and normal tissues, largely based on quantitative analyses of the outcome of randomized controlled trials. There is now increasing evidence that the use of hypofractionation may be beneficial in several of the most common radiation therapy indications. Advances in physics and technology include advances in target visualization and in in-room image guidance as well as progress in the planning and delivery of intensity modulated radiation therapy. Novel radiation modalities, proton and carbon ion beams, add further capabilities for spatial modulation of dose-time-fractionation within a patient. Novel research avenues include the possible use of biomarkers for optimizing dose-fractionation in individual patients as well as the preclinical and clinical study of dose-fractionation and dose distribution interactions when combining radiation with cytotoxic or molecular targeted drugs. All of these developments create not only challenging and exciting research opportunities but also a real hope that more cancer patients will be cured while maintaining the best possible health-related quality of life.

The invited national and international faculty and the host faculty will present an update of the current status of dose-time-fractionation biology as it applies to multi-modality, targeted cancer therapy. New research opportunities will be identified and the relevance of each of the above topics to clinical practice in Radiation Oncology will be emphasized.

Proffered Papers
Proffered papers may be submitted to DiAnne Genrich (dgenrich@humonc.wisc.edu). Registration is required for submission of an abstract for presentation. The deadline for submission of a one-page abstract for proffered papers (no special format requirements) is July 15, 2013. Primary author of the abstract accepted by the Program Committee will be notified by July 31, 2013.

Intended Audience
This conference is intended for radiation oncologists, radiobiologists, medical physicists, therapists, biological modelers, medical students and residents.

Elements of Competence
This CME activity has been designed to change learner knowledge and competence and focuses on the American Board of Medical Specialties areas of medical knowledge, patient care and procedural skills, and practice-based learning and improvement.

OBJECTIVES
At the conclusion of this activity, participants will be able to:

- Analyze the interplay between dose distribution, fractionation and chemical/biological agents.
- Identify the role of functional and molecular imaging in target volume definition, in intra-individual dose prescription and in monitoring the response to radiation therapy.
- Present and discuss the state-of-the-art of bio-effect models linking patient-specific outcome data 4D dose-time-volume data.
- Discuss the potential of chemical/molecular prognostic and predictive markers for individual treatment optimization.
- Identify mechanisms, programs and resources to further support and implement the investigational strategies described in the bullet points above.

CREDIT

Accreditation Statement
The University of Wisconsin School of Medicine and Public Health is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
The University of Wisconsin School of Medicine and Public Health designates this live activity for a maximum of 21 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Education Units
The University of Wisconsin-Madison, as a member of the University Continuing Education Association (UCEA), authorizes this program for 2.1 continuing education units (CEUs) or 21 hours.

CAMPEP and Medical Dosimetrist Certification Board (MDCB)
Application has been made to CAMPEP and MDCB for approval of this educational activity. All approved CAMPEP and MDCB CE activities will now be awarded ARRT Category A credit.

Policy on Faculty and Sponsor Disclosure
It is the policy of the University of Wisconsin School of Medicine and Public Health that the faculty, authors, planners, and other persons who may influence the content of this CME activity disclose all relevant financial relationships with commercial interests in order to allow CME staff to identify and resolve any potential conflicts of interest. Faculty must also disclose any planned discussion of unlabeled/unapproved uses of drugs or devices during their presentation(s). Detailed disclosure will be made in the course handout materials.
ORGANIZING AND PROGRAM COMMITTEE

Søren Bentzen, PhD, DSc, Professor of Human Oncology, University of Wisconsin, Madison, WI

Paul Harari, MD, Professor and Chair of Human Oncology, University of Wisconsin, Madison, WI

Robert Jeraj, PhD, Professor of Medical Physics, University of Wisconsin, Madison, WI

Bhudatt Paliwal, PhD, Professor of Medical Physics and Human Oncology, University of Wisconsin, Madison, WI

Albert van der Kogel, PhD, Professor of Human Oncology, University of Wisconsin, Madison, WI

Kristen Bradley, MD, Associate Professor of Human Oncology, University of Wisconsin, Madison, WI

Carsten Brink, PhD, Medical Physicist, Institute of Clinical Research, University of Southern Denmark, Odense, Denmark

Kevin A. Camphausen, MD, Chief, Radiation Oncology Branch, National Cancer Institute, Bethesda, MD

Don Cannon, MD, Chief Resident in Human Oncology, University of Wisconsin, Madison, WI

Yue Cao, PhD, Professor of Radiation Oncology and Biomedical Engineering, University of Wisconsin, Madison, WI

Rupak Das, PhD, Professor of Human Oncology, University of Wisconsin, Madison, WI

Joseph Deasy, PhD, Chair, Department of Medical Physics, Memorial Sloan Kettering-Cancer Center, New York, NY

Paul DeLuca, PhD, Provost of University of Wisconsin, Madison, WI

Vincent Gregoire, MD, PhD, Professor of Radiation Oncology, Universite Catholique de Louvain, Brussels, Belgium

Stephen Hahn, MD, Professor and Chair of Radiation Oncology, University of Pennsylvania, Philadelphia, PA

Paul Harari, MD, Professor and Chair of Human Oncology, University of Wisconsin, Madison, WI

Mattias Hatt, PhD, Director, Medical Research Information INSERM, Nice, France

Steven Howard, MD, Associate Professor of Human Oncology, University of Wisconsin, Madison, WI

David Jaffray, PhD, Head of Radiation Physics, Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada

Randy Kimple, MD, PhD, Assistant Professor of Human Oncology, University of Wisconsin, Madison, WI

Assen Kirov, PhD, Associate Attending Physicist, Memorial Sloan-Kettering Cancer Center, New York, NY

Kevin Kozak, MD, PhD, Assistant Professor of Human Oncology, University of Wisconsin, Madison, WI

Jan Lagendijk, PhD, Professor of Radiotherapy, University Medical Center, Utrecht, The Netherlands

T. Rockwell Mackie, PhD, Professor of Medical Physics and Human Oncology, University of Wisconsin, Madison, WI

Bhudatt Paliwal, PhD, Professor of Medical Physics and Human Oncology, University of Wisconsin, Madison, WI

Scott Perlman, MD, Professor of Radiology, University of Wisconsin, Madison, WI

Alan Rapraeger, PhD, Professor of Human Oncology, University of Wisconsin, Madison, WI

Mark Ritter, MD, PhD, Professor of Human Oncology, University of Wisconsin, Madison, WI

Lauren Shapiro, MD, Assistant Professor of Human Oncology, University of Wisconsin, Madison, WI

Jennifer Smilowitz, PhD, Associate Professor of Human Oncology, University of Wisconsin, Madison, WI

Tod Speer, MD, Associate Professor of Radiation Oncology, University of Wisconsin, Madison, WI

Randal S. Tibbetts, PhD, Associate Professor of Human Oncology, University of Wisconsin, Madison, WI

Bob Timmerman, MD, Professor of Radiation Oncology, University of Texas, Dallas, TX

Prabhakar Tripuraneni, MD, Professor and Head of Radiation Oncology, Scripps Clinic, San Diego, CA

Albert van der Kogel, PhD, Professor of Human Oncology, University of Wisconsin, Madison, WI

Ivan Vogelius, PhD, Medical Physicist of Radiation Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

FACULTY

Bethany Anderson, MD, Assistant Professor of Human Oncology, University of Wisconsin, Madison, WI

Adam Bayliss, PhD, Medical Physicist of Human Oncology, University of Wisconsin, Madison, WI

John Bayouth, PhD, Chief of Physics and Professor of Human Oncology, University of Wisconsin, Madison WI

Ed Bender, PhD, Assistant Professor of Human Oncology, University of Wisconsin, Madison, WI

Søren Bentzen, PhD, DSc, Professor of Human Oncology, University of Wisconsin, Madison, WI

Jeff Bradley, MD, Professor of Radiation Oncology, Washington University, St. Louis, MO
GENERAL INFORMATION

Dates: September 8-11, 2013
Place: Wisconsin Institutes of Discovery
330 N Orchard St, Madison, WI 53715
Telephone: 608-316-4300
Email: info@discovery.wisc.edu

Conference Fees
The conference fee includes the cost of tuition, materials, refreshment breaks, lunches, a reception, and a nonrefundable registration fee of $50. Should you cancel your registration fee by August 31, 2013, you will be refunded the entire conference fee except the $50 nonrefundable portion. Only 50% of your registration fee will be refunded after September 1, 2013.

Housing
A block of rooms has been reserved at Union South (1308 W Dayton St, Madison, WI 53715 p. 608-890-3000) for the rate of $124 plus tax and Hotel Red (501 Monroe St, Madison, WI 53711, 1-866-599-6674) for $159 plus tax. Please contact the hotel directly for your reservation and identify yourself as a member of the ICDTF/Human Oncology group. These rooms will be released to the general public on August 8, 2013.

Driving Directions
To get to info about parking: http://discovery.wisc.edu/home/discovery/plan-your-visit/parking/

For Further Information
For conference information please contact DiAnne Genrich, dgenrich@humonc.wisc.edu; phone: 608-263-9962; fax 608-890-3148, 600 Highland Avenue, K4/312 CSC, Madison, WI 53792-3684. The official website for the conference is: http://www.humonc.wisc.edu/dose.time/

Four Easy Ways to Register
Online: www.ocpd.wisc.edu/course_catalog
By Mail: Return your completed registration form and payment
By Phone: 608-262-1397. Please call and give your billing information or pay by MasterCard, VISA, or American Express
By Fax: 1-800-741-7416 (in Madison fax 265-3163)

Conference Attire
To ensure your comfort in the conference rooms, please bring a sweater or jacket to accommodate temperature variations.

Important Deadline
Proposed papers due on July 15, 2013.

REGISTRATION FORM

9th International Conference on Dose, Time and Fractionation in Radiation Oncology
September 8-11, 2013

Please print in BLOCK letters

STEP 1. Participant Information

Name
First MI Last
Professional Degree (for name tag): □ MD; □ DO; □ PhD;
□ PA; □ RN; □ Other, please specify: __________
Company Name
Work Address
City, State, Zip
Phone
Where you can be reached from 9:00 am - 5:00 pm
FAX
Where you can be reached from 9:00 am - 5:00 pm
E-Mail Address
Please print clearly
____ I request vegetarian meal options

STEP 2. Registration Fee

<table>
<thead>
<tr>
<th>Until July 31, 2013 (11:59 PM CST)</th>
<th>After July 31, 2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physicians</td>
<td>$450/person</td>
</tr>
<tr>
<td>Other Health Professionals</td>
<td>$350/person</td>
</tr>
<tr>
<td>Residents, Interns, Students*</td>
<td>$175/person</td>
</tr>
</tbody>
</table>

*Please send verification of resident, intern or student status

Payment Method:
____ PO or check enclosed (payable to University of Wisconsin)
____ Please bill my company:
____ Credit Card: □ MasterCard; □ VISA; □ AMEX
Cardholder’s Name
Card Number
Exp Date

STEP 3. Send Your Registration to:
CME Specialist, Department 101, The Pyle Center, 702 Langdon Street, Madison, WI 53706 or fax 1-800-741-7416 (in Madison fax 265-3163).

The University of Wisconsin provides equal opportunities in employment and programming, including Title IX requirements.

The University of Wisconsin School of Medicine and Public Health fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please notify DiAnne Genrich or Terese Bailey in order to receive service. Please call 608-263-9962 or 608-240-2141.
### SUNDAY, SEPTEMBER 8

**PM**

12:15 Registration

1:00 Welcome  
*Paul M. Harari, MD*

**OVERVIEW**

*Moderator: Paul Harari, MD*

1:15 From Hyper- to Hypofractionation in Radiation Oncology  
*Søren M. Bentzen, DSc*

1:45 Spinal Cord as a Model for Fractionation Studies  
*Albert van der Kogel, PhD*

2:15 Discussion

2:30 Break

**SITE SPECIFIC CONCEPTS**

*Moderator: Kristin Bradley, MD*

3:00 Prostate Cancer  
*Mark Ritter, MD, PhD*

3:20 Breast Cancer  
*Bethany Anderson, MD*

3:40 Head and Neck Cancer  
*Vincent Gregoire, MD, PhD*

4:00 Discussion

4:20 Proffered papers  
*Moderator: Tod Speer, MD*

5:00 Adjourn & Reception

### MONDAY, SEPTEMBER 9

**AM**

**LUNG CANCER**

*Moderator: Lauren Shapiro, MD*

8:00 After RTOG 0617  
*Jeff Bradley, MD*

8:30 Dose per Fraction Escalation  
*Don Cannon, MD*

9:00 Lung Cancer, Imaging Toxicity  
*John Bayouth, PhD*

9:30 Discussion

9:45 Break

**KEYNOTES**

*Moderator: Paul Harari, MD*

10:15 Fractionation in SBRT  
*Bob Timmerman, MD*

10:45 Q & A Session

11:00 Clinical Promise of Protons to Exploit Hypofractionation  
*Stephen Hahn, MD*

11:30 Q & A Session

### MONDAY, SEPTEMBER 9

**PM**

Noon Lunch

**TUMOR BIOLOGY OF (HYPO-)FRACTIONATION**

*Moderator: Randal Tibbetts, PhD*

1:00 Selecting Dose-Fractionation Using Molecular Biomarkers  
*Kevin A. Camphausen, MD*

1:30 HPV and Fractionated RT  
*Randy Kimple, MD, PhD*

2:00 Proton Therapy  
*T. Rockwell Mackie, PhD*

2:30 The Future of Image Guidance  
*David Jaffray, PhD*

3:00 Discussion

3:30 Break

### TUESDAY, SEPTEMBER 10

**AM**

**MOLECULAR TARGETED AGENTS COMBINED WITH RADIATION**

*Moderator: Alan Rapraeger, PhD*

8:00 Next Generation EGFR Agents  
*Paul Harari, MD*

8:30 DNA Damage Response: Opportunities for Molecular Radiosensitization  
*Randal S. Tibbetts, PhD*

9:00 New Vascular and Antiangiogenic Agents  
*Kevin Kozak, MD, PhD*

9:30 Discussion

10:00 Break

**IMAGING TECHNOLOGIES FOR THERAPY**

*Moderator: Bhudatt Paliwal, PhD*

10:30 Combining Imaging and Delivery Systems  
*Jan Lagendijk, PhD*

11:00 ViewRay  
*Prabhakar Tripuraneni, MD*

11:30 Discussion
PM
Noon Lunch

DOSE-PAINTING
Moderator: Adam Bayliss, PhD
1:00 Where are we with Dose Painting? Robert Jeraj, PhD
1:30 Dose Painting Based on Recurrence Risk Ed Bender, PhD
2:00 Linking FDG PET to Recurrences in HNSCC Ivan Vogelius, PhD
2:30 Extracting Biological Information from Routine CBCT Carsten Brink, PhD
3:00 Discussion
3:15 Break

IMAGING FOR TARGET DEFINITION
Moderator: Jennifer Smilowitz, PhD
3:30 How Well do we Know Where the Target is? Assen Kirov, PhD
4:00 Advanced Methods for Target Definition Mattias Hatt, PhD
4:30 Discussion
5:00 Adjourn

WEDNESDAY, SEPTEMBER 11

AM IMAGING FOR TREATMENT RESPONSE ASSESSMENT
Moderator: Steven Howard, MD
8:00 PET Response Assessment in Lung Cancer Scott Perlman, MD
8:30 MRI Response Assessment in GBM Yue Cao, PhD
9:00 TCP and NTCP Models: Current Status on Treatment Plan Optimization Joseph Deasy, PhD
9:30 Discussion
10:00 Break
10:30 Panel
11:30 Conference Summary

PM Noon Adjourn